XOMA to Present at H.C. Wainwright BioConnect Investor Conference
On April 26, 2023, XOMA Corporation (NASDAQ: XOMA) announced that Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference. This event is scheduled for May 2, 2023, at 10:30 AM ET. Investors can access the chat through a link provided or via the investor relations section of XOMA's website. A replay of the discussion will be available for 90 days post-event.
XOMA operates as a biotechnology royalty aggregator, acquiring future economic rights tied to pre-commercial therapeutic candidates. With over 70 assets in its portfolio, it provides non-dilutive funding to biotech companies. For more information, visit www.xoma.com.
- None.
- None.
EMERYVILLE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 10:30 AM ET.
The fireside chat can be accessed at https://bit.ly/403aHUp or by visiting the investor relations section of the Company’s website at www.xoma.com. A replay of the conversation will be available and archived on the site for 90 days after the event.
About XOMA Corporation
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
EXPLANATORY NOTE:
Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except Vabysmo® (faricimab) and IXINITY® [coagulation factor IX (recombinant)], are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.
| XOMA Investor Contact | XOMA Media Contact |
| Juliane Snowden | Kathy Vincent |
| XOMA Corporation | KV Consulting & Management |
| +1 646-438-9754 | +1 310-403-8951 |
| juliane.snowden@xoma.com | kathy@kathyvincent.com |
FAQ
When will XOMA's fireside chat at the H.C. Wainwright BioConnect Investor Conference take place?
Who from XOMA will be featured in the fireside chat?
How can I access the XOMA fireside chat?
What is XOMA Corporation's role in the biotechnology industry?
How many assets does XOMA have in its portfolio?
